Robert P. Edwards
YOU?
Author Swipe
View article: Figure S5 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Figure S5 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy Open
Supplementary Figure 5. Schematic of FST CRISPR KO guides and in vivo experiment. A. Binding of the two commercially available FST CRISPR guides to FST to mediate KO. B. Mice were injected with SKOV3 cells expressing FST sgRNA #2. Mice wer…
View article: Figure S4 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Figure S4 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy Open
Supplementary Figure 4. The effect of ATF2 siRNA on gene expression and PT340 FST induced chemoresistance. A. Schematic detailing the transwell experiments. CellTrace Violet cells were sorted for rapidly dividing (Dim) or quiescent cells (…
View article: Figure S1 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Figure S1 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy Open
Supplementary Figure 1. Histological analysis of PT340 cell line. PT340 cells were injected into NSG mice, and the resulting tumors were harvested for histological analysis, H&E staining showed features of Clear Cell Ovarian Carcinoma.
View article: Figure S2 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Figure S2 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy Open
Supplementary Figure 2. RNA-seq analysis. A. Schematic of the RNA-seq experimental design. B. Waterfall plot of RNA-seq data showing the 141 genes which were DE at all time points compared to luciferase control in HEY1 and SKOV3 cell lines…
View article: 1343 A phase II trial of combination locoregional chemoimmunotherapy in recurrent platinum-sensitive ovarian cancer triggers a T lymphotactic response correlating with clinical outcomes
1343 A phase II trial of combination locoregional chemoimmunotherapy in recurrent platinum-sensitive ovarian cancer triggers a T lymphotactic response correlating with clinical outcomes Open
View article: Medical comorbidities prognosticate survival in glioblastoma
Medical comorbidities prognosticate survival in glioblastoma Open
View article: IFNγ-mediated suppression of alternative NF-κB in tumor-resident myeloid cells promotes selective recruitment of cytotoxic but not regulatory T cells
IFNγ-mediated suppression of alternative NF-κB in tumor-resident myeloid cells promotes selective recruitment of cytotoxic but not regulatory T cells Open
Immunotherapy is currently effective in less than half of patients with solid tumors, and most responders develop secondary progression. High infiltration of the tumor microenvironment (TME) with CD8 + cytotoxic T cells (CTLs) and low infi…
View article: Murine cell lines with defined mutations model different histological subtypes of epithelial ovarian cancer
Murine cell lines with defined mutations model different histological subtypes of epithelial ovarian cancer Open
Preclinical modeling of epithelial ovarian cancer in immune-competent mice progressing to orthotopic, spontaneous tumors is challenging, requiring multiple genetic modifications in the host. Transplantable models using cell lines are easie…
View article: All-cause mortality and neighborhood social vulnerability among women with ovarian cancer
All-cause mortality and neighborhood social vulnerability among women with ovarian cancer Open
View article: Supplementary Table S1 from A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers
Supplementary Table S1 from A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers Open
Patient level data of 16 evaluable patients with vulvar cancers treated on the DART immunotherapy protocol
View article: Data from A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers
Data from A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers Open
Purpose:Dual PD-1/CTLA-4 inhibition shows promise in various malignancies. The SWOG S1609 Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART) trial presents initial results of ipilimumab/nivolumab in vulvar cancers.Patients and M…
View article: Supplementary Table S2 from A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers
Supplementary Table S2 from A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers Open
Representativeness of Study Participants
View article: A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers
A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers Open
Purpose: Dual PD-1/CTLA-4 inhibition shows promise in various malignancies. The SWOG S1609 Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART) trial presents initial results of ipilimumab/nivolumab in vulvar cancers. Patients and…
View article: 614 T-regulatory cell depletion with E7777 combined with pembrolizumab in patients with recurrent solid tumors: phase I trial
614 T-regulatory cell depletion with E7777 combined with pembrolizumab in patients with recurrent solid tumors: phase I trial Open
View article: Figure S6 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs
Figure S6 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs Open
DNAM-1 signaling assists TCR signaling in CTLs.
View article: Figure S1 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs
Figure S1 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs Open
DNAM-1 and NKG2D expression is correlated with long term survival and cytotoxic genes in tumor samples from melanoma patients (TCGA).
View article: Figure S3 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs
Figure S3 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs Open
DC-primed MART-1-specific CTLs express high levels of NKRs, but recognize and kill cancer cells in a strictly TCR-dependent manner.
View article: Figure S5 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs
Figure S5 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs Open
Human peripheral blood CD8+ T cells require NKR-mediated co-stimulation for optimal effector response to weak TCR stimulation.
View article: Figure S4 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs
Figure S4 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs Open
NKRs assist CTLs to recognize and conjugate cancer cells expressing low-level MHCI/peptide complexes.
View article: Figure S7 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs
Figure S7 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs Open
Chemotherapeutic drugs elevate NKR-L expression on cancer cells.
View article: Figure S2 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs
Figure S2 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs Open
Expression of DNAM-1 and DNAM-1-competing (inhibitory) receptors reflects CTL cytotoxic function.
View article: Data from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs
Data from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs Open
Cytotoxic CD8+ T lymphocyte (CTL) recognition of non-mutated tumor-associated antigens (TAA), present on cancer cells and also in healthy tissues, is an important element of cancer immunity, but the mechanism of its selectivity …
View article: Therapeutic Anti-Tumor Efficacy of DC-Based Vaccines Targeting TME-Associated Antigens Is Improved When Combined with a Chemokine-Modulating Regimen and/or Anti-PD-L1
Therapeutic Anti-Tumor Efficacy of DC-Based Vaccines Targeting TME-Associated Antigens Is Improved When Combined with a Chemokine-Modulating Regimen and/or Anti-PD-L1 Open
We previously reported that dendritic cell (DC)-based vaccines targeting antigens expressed by tumor-associated vascular endothelial cells (VECs) and pericytes effectively control tumor growth in translational mouse tumor models. In the cu…
View article: 799 Combination intraperitoneal chemoimmunotherapy triggers a T-cell chemotactic locoregional response in patients with recurrent platinum-sensitive ovarian cancer
799 Combination intraperitoneal chemoimmunotherapy triggers a T-cell chemotactic locoregional response in patients with recurrent platinum-sensitive ovarian cancer Open
Background The increased prevalence of CD8+ tumor-infiltrating lymphocytes (TIL) in the tumor microenvironment (TME) correlates with improved outcomes in patients with epithelial ovarian cancer (EOC). We hypothesize that a combination of i…
View article: NK Receptors Replace CD28 As the Dominant Source of Signal 2 for Cognate Recognition of Cancer Cells by TAA-specific Effector CD8+ T Cells
NK Receptors Replace CD28 As the Dominant Source of Signal 2 for Cognate Recognition of Cancer Cells by TAA-specific Effector CD8+ T Cells Open
CD28-driven “signal 2” is critical for naïve CD8 + T cell responses to dendritic cell (DC)-presented weak antigens, including non-mutated tumor-associated antigens (TAAs). However, it is unclear how DC-primed cytotoxic T lymphocytes (CTLs)…
View article: Is Programmed Death Ligand 1(PD-L1) Expression in Vulvar Cancer Prognostic for Locoregional Control?
Is Programmed Death Ligand 1(PD-L1) Expression in Vulvar Cancer Prognostic for Locoregional Control? Open
View article: Prognostic Significance of Tumor-infiltrating Lymphocytes and Anti-programmed Death-ligand 1 Therapy in Sinonasal Mucosal Melanoma: A 10-year Experience at a Single Institution
Prognostic Significance of Tumor-infiltrating Lymphocytes and Anti-programmed Death-ligand 1 Therapy in Sinonasal Mucosal Melanoma: A 10-year Experience at a Single Institution Open
Background and objectivesSinonasal mucosal melanoma (SNMM) is a rare aggressive malignancy that presents with dismal outcomes and a high metastatic propensity. The prognostic factors as well as therapeutic regimens remain largely unknown d…
View article: A globally integrated structure of taxonomy to support biodiversity science and conservation
A globally integrated structure of taxonomy to support biodiversity science and conservation Open
View article: Mouse Behavior - Open Field and T-Maze v1
Mouse Behavior - Open Field and T-Maze v1 Open
This protocol describes two behavioral tasks for mice. The first is the Open Field Test, which is used to asses motor behavior, and the second is the T-Maze, which is used to assess spatial learning.
View article: Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition Open
The objective was to correlate CD47 gene expression with resistance to immune checkpoint inhibitors (ICI) in tumor tissue of gynecological cancer (GC). Further, we sought to assess the efficacy of targeting CD47 pathway alone and in combin…